ProKidney Corp. (NASDAQ: PROK) completed patient enrollment for the accelerated approval efficacy analysis of its Phase 3 REGEN-006 (PROACT 1) study, positioning the company for pivotal topline results on eGFR slope anticipated in the second quarter of 2027. This clinical milestone coincides with the company’s second-quarter 2026 financial report, which showed a net loss before noncontrolling interest of $46.4 million, widening from $37.0 million in the same period last year, while maintaining a cash position of $181.6 million to support operations into mid-2027.

The financial results reflect increased investment in clinical development alongside controlled administrative spending. Revenue from operations stood at $150 thousand for the quarter, beating analyst estimates but declining 32.13 percent year-over-year from $221 thousand. The company appointed Kenneth Locke as Chief Technical Officer in June 2026, leveraging his experience in R&D and supply chain to prepare for future regulatory milestones.

Financial Performance Overview

ProKidney’s bottom-line pressure intensified as research and development (R&D) expenses rose significantly to fund the ongoing PROACT 1 study. R&D costs reached $36.1 million in Q2 2026, up from $25.9 million in Q2 2025, driven primarily by an $8.7 million increase in clinical study and related manufacturing costs. Conversely, general and administrative (G&A) expenses decreased by $1.6 million to $12.4 million, aided by lower compensation costs due to the vesting of prior equity awards and reduced severance costs.

The net loss attributable to Class A common stockholders was $28.4 million, resulting in a basic and diluted net loss per share of $(0.15). This represents a miss against the consensus estimate of $(0.14) and a deterioration from the $(0.13) loss per share recorded in Q2 2025.

Clinical Development Updates

The PROACT 1 study is a Phase 3, randomized, blinded, sham-controlled trial evaluating rilparencel in patients with advanced chronic kidney disease (CKD) and type 2 diabetes. The recently completed accelerated approval analysis subset includes approximately 320 patients and uses annualized eGFR slope as the surrogate endpoint. Topline results for this analysis are expected in Q2 2027.

ProKidney remains on track to complete full enrollment of approximately 470 patients in the second half of 2026. This larger cohort will support the confirmatory composite time-to-event analysis, with topline results anticipated in the second half of 2029. The study focuses on patients with Stage 4 CKD and late Stage 3b CKD with accompanying albuminuria.

What the Numbers Show

The divergence between rising R&D spend and stable revenue underscores ProKidney’s late-stage clinical profile. The $10.2 million increase in R&D expenses is directly tied to the PROACT 1 study, indicating that capital deployment is prioritized for data generation rather than commercial scaling. With $181.6 million in cash and marketable securities as of June 30, 2026, the company has sufficient liquidity to fund operations through mid-2027 without immediate need for additional financing. However, the widening net loss per share suggests that profitability remains distant, dependent entirely on the successful regulatory outcome of the PROACT 1 trial.